Stocksigma LogoStocksigma Logo

Aurobindo Pharma Secures USFDA Final Approval for Generic Fycompa Tablets

Aurobindo Pharma received USFDA final approval on 3rd Oct'26 to manufacture and market Perampanel Tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg)

Aurobindo Pharma Secures USFDA Final Approval for Generic Fycompa Tablets

Aurobindo Pharma Ltd 路 Press Release 路 03 Oct 2026, 10:39 pm

Aurobindo Pharma Secures USFDA Final Approval for Generic Fycompa Tablets Aurobindo Pharma received USFDA final approval on 3rd Oct'26 to manufacture and market Perampanel Tablets (2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg), bioequivalent to Catalyst Pharmaceuticals' Fycompa. Indicated for epilepsy seizures, the product addresses a US$ 67 million market (IQVIA MAT Aug'26). Manufacturing will occur at wholly owned subsidiary APL Healthcare's Unit-IV, with a planned launch in Q3FY27. This brings Aurobindo's cumulative USFDA tally to 599 ANDA approvals, comprising 574 final and 25 tentative approvals.

Original exchange filing (PDF)

More announcements from Aurobindo Pharma Ltd

All Aurobindo Pharma Ltd announcements